GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Those who cannot tolerate ACE inhibitors may be treated with an angiotensin II receptor antagonist. Statin therapy has been shown to reduce mortality and subsequent cardiac events and should be commenced to lower LDL cholesterol. Other medications, such as ezetimibe, may also be added with this goal in mind. Aldosterone antagonists (spironolactone or eplerenone) may be used if there is evidence of left ventricular dysfunction after an MI, ideally after beginning treatment with an ACE inhibitor.
The success of these concerts led to an appearance at the Classic Northwest concert at Safeco Field, opening again for the Eagles. The band took the last leg of their 2017 world tour to Europe, opening for Steely Dan. They toured again with Steely Dan the following year. This tour began in Charlotte, North Carolina and concluded in Bethel, New York. Former Allman Brothers percussionist Marc Quiñones joined the band in May 2018, and the band performed the Toulouse Street and The Captain and Me albums in their entirety along with a selection of hits, at the Beacon Theatre in New York City on November 15–16, 2018. These shows marked their first time at the theatre in 25 years. The concerts were recorded and released as a live album in 2019. During the summer of 2019, the band toured with Santana. Also in 2019, the band performed at the Ryman Auditorium in Nashville and performed the Toulouse Street and The Captain and Me albums in their entirety once again. Michael McDonald joined the band for an encore and they performed "Takin' It to the Streets". At the end of the concert, Simmons announced that McDonald would re-join the band for their 50th Anniversary tour. Since the early 2000s, they have headlined and performed at many benefit concerts including former manager Cohn's B.R. Cohn Winery in Glen Ellen where they had also shared the stage with McDonald in 2006 and 2012. Cohn sold his winery in 2015 to set his primary focus on managing the band and the B.R Cohn Charity Fall Music Festival was relocated to the Sonoma Valley Field of Dreams.
=== Protein and organic metabolites === In all forms of life, most of the sulfur is contained in two proteinogenic amino acids (cysteine and methionine), thus the element is present in all proteins that contain these amino acids. Some of the sulfur is present in certain metabolites—many of which are cofactors—and sulfated polysaccharides of connective tissue (chondroitin sulfates, heparin).
Sources: en.wikipedia.org
Glass is incredibly chemically stable and durable, when handled carefully (due to its fragile nature). Therefore, this packaging material is an ideal candidate for repeated use, due to these characteristics. Glass can also be recycled multiple times without losing any quality properties. Multi-layer packaging: in the food and beverage business, packaging composed of numerous layers of various materials is commonly referred to as multi-layer or multi-material packaging. In many countries, multi-material food packaging is frequently burned or disposed of in landfills. Nevertheless, some areas are actively developing separate collections and efficient sorting processes for fiber-based multi-material packaging, such as beverage cartons. On the other hand, multi-layer packaging composed of aluminum and plastic barrier, cannot currently be recycled in an efficient way, and must undergo chemical treatment to be disposed of correctly. In light of these considerations, it is clear how, despite being the state-of-the-art in food packaging applications, multi-layer packaging poses a great challenge when considering its end-of-life. An exception is the case of multi-layer packaging consisting of several layers of the same material (or being part of the same category): such solutions in many cases allow for outstanding performance and, at the same time, allow for an easier recycling.
After independence in 1947, India shifted from the colonial economic model to a focus on industrialisation and poverty reduction. This transition brought a large expansion of government authority. Government spending as a share of gross domestic product (GDP) increased from 3 to 5 per cent in 1931 to 22 per cent by 1981. Public administration and state-owned enterprises became major employers. To manage this market intervention, India developed—during the 1950s—a comprehensive, federally managed statistical system to conduct large-scale sample surveys for monitoring and assessing living standards or effects of interventions. The Indian state utilised fiscal policy and international assistance to fund capital-intensive industrialisation and subsidise basic goods such as food, fertilisers, and electric power. However, by the 1970s, this heavy public spending became unsustainable. Domestic economic growth slowed, leading to a balance-of-payments crisis, whereas government spending flattened around 28–30 per cent of GDP. Government-led planning yielded mixed results. Many of India’s big economic changes were not planned by government bureaucrats. Thus, the 1970s Green Revolution, mass labour migration to the Middle East, and a garment-industry boom all emerged from global market forces and non-state actors; the government simply adapted to them after they were underway. A major shift occurred during the 1990s as India rejoined the global economy. The Indian government reduced import tariffs and enacted pro-market reforms.
Almost exclusively affects women. Starts or worsens at times of hormonal changes: puberty, pregnancy, or menopause. Bilateral, symmetrical buildup of fat in the legs, and sometimes arms and lower trunk, that is resistant to nutritional intervention, exercise, elevation, diuretics, and bariatric surgery. Feet/hands are typically spared, presenting with a raised ridge or fold of fat. In earlier stages, there may be a subtle, raised ridge or fold of fat instead of distinct cuffing to the ankle or wrist. Sometimes, especially in later stages, this increased adipose tissue above the ankle/wrist can cause the appearance of a “cuff” (“pantaloons” is an evocative term sometimes to describe this morphology in later stages). Presence of nodular and/or fibrotic texture beneath the skin, which can create an uneven, dimpled appearance. Complaints of pain, tenderness, and/or heaviness in affected areas. Fatigue, brain fog, easy bruising. Edema and joint hypermobility may also be present. Texture and visual presentation may change with swelling and inflammation.
Sources: en.wikipedia.org
Anatomical pathology (Commonwealth) or anatomic pathology (United States) is a medical specialty that is concerned with the diagnosis of disease based on the gross, microscopic, chemical, immunologic and molecular examination of organs, tissues, and whole bodies (as in a general examination or an autopsy). Anatomical pathology is itself divided into subfields, the main divisions being surgical pathology, cytopathology, and forensic pathology. Anatomical pathology is one of two main divisions of the medical practice of pathology, the other being clinical pathology, the diagnosis of disease through the laboratory analysis of bodily fluids and tissues. Sometimes, pathologists practice both anatomical and clinical pathology, a combination known as general pathology.
Measurements of the Zeeman effect commonly involve the use of a Fabry–Pérot interferometer, with light from a source (placed in a magnetic field) being passed between two mirrors of the interferometer. If δD is the change in mirror separation required to bring the mth-order ring of wavelength λ + Δλ into coincidence with that of wavelength λ, and ΔD brings the (m + 1)th ring of wavelength λ into coincidence with the mth-order ring, then
== Pharmacokinetics == The major source of retinoids in the human diet is plant pigments such as carotenes and retinyl esters derived from animal sources. Retinyl esters are transported through the chylomicron pathway to the liver or fat tissue while retinol or carotenes are transported from the enterocytes to the liver and are processed into retinyl esters by LRAT for storage. Most synthetic retinoids are absorbed when taken orally, while topical retinoids cannot diffuse through the skin barrier unless it is compromised. All classes of retinoid bind to many proteins. Natural retinoids such as retinol and retinyl esters bind to carrier proteins such as RBP4, chylomicrons and VLDL while synthetic retinoids likely bind to these and other proteins. First generation retinoids are rapidly metabolized by Cytochrome p450 enzymes, typically of the Cyp26 family.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.